Despite what the name suggests, Polyendocrine Metabolic Ovarian Syndrome isn’t just about ovaries—or cysts, for that matter. In fact, many people diagnosed with PMOS don’t have any ovarian cysts at all. Confusing? You’re not alone. The name dates back to how the condition was first described, but science has come a long way since then. Today, we understand that PCOS is really a complex hormonal and metabolic condition that affects far more than reproductive health.
At its core, PMOS is about hormonal imbalance. When key hormones like insulin, androgens (like testosterone), and others are out of sync, they can create a domino effect throughout the body. This hormonal miscommunication can lead to irregular periods, acne, weight changes, hair loss or excess hair growth, difficulty with ovulation or fertility—and that’s just the shortlist. But here’s the thing: PMOS doesn’t follow a single pattern. Some women experience textbook symptoms. Others don’t fit the mold at all. That’s part of what makes PMOS so challenging—and why understanding your unique experience matters.
So, how can the PMOS Association help?
We’re here to offer more than definitions. We’re here to offer direction. Whether you’re newly diagnosed, still searching for answers, or years into your journey and feeling stuck, we’re committed to helping you make sense of PMOS—and make progress.
Here’s what you’ll find at PMOSA:
✅ Reliable, science-backed information about what PMOS is (and isn’t)
💬 Supportive communities of people who understand exactly what you’re going through
🧬 Resources for navigating fertility, metabolic health, nutrition, and more
🧠 Education for providers who want to better support their PMOS patients
🙋♀️ Advocacy to make sure PMOS is recognized, researched, and respected
No fluff. No fad cures. Just real support, grounded in evidence and compassion.
At PMOSA, we believe every person with PCOS deserves to be informed, empowered, and heard. Wherever you are in your journey, we’re honored to walk with you.
pcos: Latest results from PubMed
CONCLUSION: Aerobic exercise, especially HIIT, appears effective in improving regional fat distribution, LDL cholesterol, and insulin resistance in PCOS women, though evidence for BMI and hormonal changes remains inconclusive. Larger, longer-term RCTs are needed to confirm these findings and clarify hormonal outcomes.
Published on: Sat, 15 Aug 2026 06:00:00 -0400
Authors: Rohit Gautam, Pratibha Maan, Sasidharan Sivakumar, Amit Arora, Saubhagya Kumar Jena, Taruna Arora,
CONCLUSION: Twelve weeks of N. sativa oil supplementation were associated with significant improvements in inflammatory status and fasting blood glucose compared with placebo after baseline adjustment. However, no significant between-group effects were observed for insulin resistance indices or hormonal outcomes. These findings support the potential adjunctive role of N. sativa oil in PCOS while highlighting the need for larger adequately powered clinical trials.
Published on: Fri, 14 Aug 2026 06:00:00 -0400
Authors: Samaneh Jamshidian, Faranak Jalilvand,
The recent proposal to rename 'polycystic ovary syndrome' (PCOS) as 'polyendocrine metabolic ovarian syndrome' (PMOS) reflects an important attempt to reconsider disease nomenclature in light of contemporary understanding of the syndrome. However, although the limitations of the term 'PCOS' are well recognized, the proposed terminology raises conceptual, biological and clinical concerns. 'PMOS' appears to redefine the syndrome through an expansive multisystem framework in which endocrine and...
Published on: Fri, 14 Aug 2026 06:00:00 -0400
Authors: Maria Longo, Antonio La Marca,
Polyendocrine metabolic ovarian syndrome [PMOS; previously known as polycystic ovary syndrome (PCOS)] is an endocrine condition affecting 10%-13% of women of reproductive age, with cardiometabolic, reproductive and psychological features. The PMOS guidelines have established recommendations for its management, which can include pharmacological, lifestyle and/or traditional medicines. The aim of this narrative review is to explore the pathophysiology, treatment recommendations and current...
Published on: Fri, 14 Aug 2026 06:00:00 -0400
Authors: Margaret McGowan, Stephanie Cowan, Chau Thien Tay, Lisa J Moran, Ashley H Ng,
The genetic architecture of polycystic ovary syndrome (PCOS) has not been fully elucidated. Translating genome-wide association study (GWAS) loci into functional effector genes represents a key challenge for elucidating disease mechanisms and advancing targeted therapeutic strategies. In this study, the FinnGen R12 dataset was utilized in conjunction with the Genotype-Tissue Expression Project (GTEx) v8 eQTL dataset to conduct cross-tissue transcriptome-wide association studies (TWAS). External...
Published on: Fri, 14 Aug 2026 06:00:00 -0400
Authors: Ruiqi Guo, Dequan Liao, Jixian Huang, Bing Dong,
STUDY QUESTION: Are young women with anti-Müllerian hormone (AMH) levels suggesting polycystic ovarian morphology (PCOM) at baseline better protected against chemo-induced ovarian damages?
Published on: Fri, 14 Aug 2026 06:00:00 -0400
Authors: C Decanter, C Legrand, H Behal, A Mailliez, D Cavalieri, E D'Orazio, P Pigny,
CONCLUSION: Serum ANGPTL8 levels are significantly lower in PCOS patients and inversely associated with PCOS risk. ANGPTL8 shows promise as a novel diagnostic biomarker for PCOS, especially when integrated into multi-marker panels with existing hormonal parameters.
Published on: Fri, 14 Aug 2026 06:00:00 -0400
Authors: Yanli Wang, Chongbo Du, Xuejia Guo, Xiaowen Ma, Yanping Feng, Yandong Deng, Yuxiao Zhang,
Adropin is a new protein that regulates energy homeostasis. The serum and follicular fluid (FF) levels of adropin are decreased in women with polycystic ovarian syndrome (PCOS); however, its role in ovarian function is unknown. The aims were to determine the expression of adropin and its receptor G protein-coupled receptor 19 (GPR19) in human granulosa cells (GC), its immunolocalization and its in vitro effects on GC function. Blood plasma, FF and GC samples were obtained from normal weight,...
Published on: Fri, 14 Aug 2026 06:00:00 -0400
Authors: Patrycja Kurowska, Monika Dawid, Natalia Respekta-Długosz, Julia Oprocha, Oliwia Szkraba, Marek Skrzypski, Noémie Couty, Christelle Ramé, Fabrice Guérif, Jakub Wyroba, Joanna Kochan, Lechosław Gajda, Monika Trzcińska, Joelle Dupont, Agnieszka Rak,
CONCLUSION: Our study demonstrated that 11.75% of women with PCOS achieved complete clinical remission following targeted metabolic pharmacotherapy, as evidenced by restored ovarian morphology, normalized testosterone concentrations, and regular menstrual cycles.
Published on: Fri, 14 Aug 2026 06:00:00 -0400
Authors: Keying Su, Yujie Zhao, Huihui Chai, Meili Cai, Diliqingna Dilimulati, Yuqin Zhang, Xiaowen Shao, Shen Qu, Chang Liu, Manna Zhang,
INTRODUCTION: Polycystic ovary syndrome (PCOS) is the leading cause of anovulatory infertility and is consistently associated with poor oocyte developmental competence, yet the molecular basis of this qualitative defect remains poorly defined. Because the germinal vesicle (GV)-to-metaphase II (MII) transition occurs under global transcriptional silence and depends entirely on the post-transcriptional remodeling of pre-stored maternal mRNAs, we hypothesized that PCOS may selectively disrupt this...
Published on: Fri, 14 Aug 2026 06:00:00 -0400
Authors: Wenchen Du, Jiayu Shi, Jie Chen, Mengyu Zhang, Xiaojie Jiang, Ruxin Wang, Yong Tan,
No abstract
Published on: Fri, 14 Aug 2026 06:00:00 -0400
Authors: Laura J den Hartigh, Mita Varghese,
CONCLUSION: JFP improved endocrine and ovarian dysfunction in letrozole-induced PCOS rats, with its effects associated with modulation of CYP17A1/CYP19A1-mediated steroidogenesis, PI3K/Akt/mTOR-related signaling, and inflammatory-apoptotic pathways. These findings provide preclinical evidence and mechanistic clues for further investigation of JFP in PCOS-related reproductive endocrine disturbance and ovarian histomorphological abnormalities, while direct ovulation and fertility outcomes require...
Published on: Thu, 13 Aug 2026 06:00:00 -0400
Authors: Hexin Li, Ming Chen, Shuangbing Deng, Jiaqi Shi, Yuntong Shi, Zichen Wan, Chengxu Zhang, Qiong Wu, Jinzhi Qu, Junyi Ruan, Jieqing Liu,
Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition with metabolic and hormonal comorbidities. This study analyzed the association between HS and polycystic ovary syndrome (PCOS) using data from the National Institute of Health's All of Us Research Program database. In a cross-sectional analysis of 78,742 females, 5.64% of those with HS had PCOS compared with 0.93% of those without HS. After adjusting for age, race/ethnicity, smoking status, type 2 diabetes, and obesity,...
Published on: Thu, 13 Aug 2026 06:00:00 -0400
Authors: Minka Gill, Nickoulet Babaei, Dahyeon Kim, Mireya Cervantes, Seanna Yang, Jashin J Wu,
CONCLUSIONS: 11-oxygenated androgens are elevated in PMOS in a phenotype-specific manner and are strongly suppressed by OCPs, with modest response to metformin and no short-term effect from LSM, supporting their utility in phenotyping and treatment monitoring.
Published on: Thu, 13 Aug 2026 06:00:00 -0400
Authors: Anuja Dokras, Allen R Kunselman, Christina M Stetter, Michael McPhaul, Frank Z Stanczyk, Richard S Legro,
CONCLUSIONS: In patients with PCOS and high metabolic risk, OCP use resulted in improved HDL-C function and a mixed effect on lipoproteins and apolipoproteins, with no clear benefit from metformin. These findings do not support or refute the cardiovascular risk-benefit of OCP use in PCOS and highlight the need for studies evaluating long-term clinical outcomes.
Published on: Thu, 13 Aug 2026 06:00:00 -0400
Authors: Iris T Lee, Daniel E Soffer, Alan T Remaley, Martin P Playford, Nehal N Mehta, Christos Coutifaris, Richard S Legro, Anuja Dokras,